PP  Vol.5 No.2 , February 2014
Safety, Tolerability, and Pharmacokinetics of E3030, a Novel Peroxisome Proliferator-Activated Receptor α/γ Dual Agonist, in Healthy Japanese Male Subjects
Abstract: Objective: The objectives of the present study were to evaluate the safety of single oral dose E3030 in healthy Japanese male subjects, and to evaluate pharmacokinetics after single oral dose E3030 and food effect on pharmacokinetic profiles. Methods: This study was conducted in a randomized, double-blind, placebo-controlled, ascending single-dose study in 56 healthy Japanese male subjects. Subjects were orally administered E3030 (0.5-40 mg) or placebo. Results: Six of 42 (14%) subjects’ administered E3030 experienced adverse events; however, all adverse events were mild and transient, and there was no dose-dependent increase in any adverse event. Plasma samples were collected over 96 hours after dosing. After administration in the fasted state, Cmax of E3030 was achieved between 1.00 and 1.75 hours, indicating rapid absorption. Both Cmax and AUC were dose-proportional in the range of 0.5 to 40 mg. The average range of elimination half-life was 18.4-23.8 hr. CL/F and Vz/F also remained nearly constant regardless of dose levels. In addition, food effect was exploratorily evaluated in five subjects of administered E3030 (10 mg) in both fasted and fed states. The fed/fasted ratios for the geometric mean of the Cmax and AUC were 0.803 and 0.913, respectively. Conclusion: E3030 was safe and well tolerated at single doses up to 40 mg. The pharmacokinetic profile showed good linearity, and food effect on pharmacokinetics of E3030 was not significant.
Cite this paper: Y. Takeuchi, Y. Nishioka, Y. Kitahara, S. Hasegawa and A. Ohnishi, "Safety, Tolerability, and Pharmacokinetics of E3030, a Novel Peroxisome Proliferator-Activated Receptor α/γ Dual Agonist, in Healthy Japanese Male Subjects," Pharmacology & Pharmacy, Vol. 5 No. 2, 2014, pp. 139-148. doi: 10.4236/pp.2014.52019.

[1]   J. A. Dormandy, B. Charbonnel, D. J. Eckland, et al., “Secondary Prevention of Macrovascular Events in Patients with Type 2 Diabetes in the PROactive Study (PRO Spective Pioglit Azone Clinical Trial in MacroVascular Events): A Randomised Controlled Trial,” Lancet, Vol. 366, No. 9493, 2005, pp. 1279-1289.

[2]   A. Keech, R. J. Simes, P. Barter, et al., “Effects of Long-Term Fenofibrate Therapy on Cardiovascular Events in 9795 People with Type 2 Diabetes Mellitus (the FIELD Study): Randomised Controlled Trial,” Lancet, Vol. 366, No. 9500, 2005, pp. 1849-1861.

[3]   ACCORD Study Group, H. N. Ginsberg, M. B. Elam, L. C. Lovato, et al., “Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus,” New England Journal of Medicine, Vol. 362, No. 17, 2010, pp. 1563-1574.

[4]   M. Jun, C. Foote, J. Lv, et al., “Effects of Fibrates on Cardiovascular Outcomes: A Systematic Review and Meta-Analysis,” Lancet, Vol. 375 No. 9729, 2010, pp. 1875-1884.

[5]   S. Kasai, T. Inoue, H. Yoshitomi, et al., “Antidiabetic and Hypolipidemic Effects of a Novel Dual Peroxisome Proliferator-Activated Receptor (PPAR) α/γ Agonist, E3030, in db/db Mice and Beagle Dogs,” Journal of Pharmacological Sciences, Vol. 108, No. 1, 2008, pp. 40-48.

[6]   Food and Drug Administration, “Guidance for Industry and Reviewers: Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in Adult Healthy Volunteers,” Draft Guidance, USDHHS, FDA, CDER, CBER, 2002.

[7]   T. Hashimoto, H. Kasai, M. Yamada, et al., “Statistical Assessment of Linear Pharmacokinetics in Clinical Pharmacological Studies,” Xenobiotic Metabolism and Disposition, Vol. 16, No. 3, 2001, pp. 244-252.

[8]   Food and Drug Administration, “Guidance for Industry: Food-Effect Bioavailability and Fed Bioequivalence Studies,” FDA, CDER, 2002.

[9]   T. M. O’Moore-Sullivan and J. B. Prins, “Thiazolidinediones and Type 2 Diabetes: New Drugs for an Old Disease,” Medical Journal of Australia, Vol. 176, No. 8, 2002, pp. 381-386.

[10]   R. R. Henry, A. M. Lincoff, S. Mudaliar, et al., “Effect of the Dual Peroxisome Proliferator-Activated Receptor-α/γ Agonist Aleglitazar on Risk of Cardiovascular Disease in Patients with Type 2 Diabetes (SYNCHRONY): A Phase II, Randomised, Dose-Ranging Study,” Lancet, Vol. 374, No. 9684, 2009, pp. 126-135.

[11]   W. C. Roberts, “Safety of Fenofibrate—US and Worldwide Experience,” Cardiology, Vol. 76, No. 3, 1989, pp. 169-179.

[12]   G. F. Blane, “Comparative Toxicity and Safety Profile of Fenofibrate and Other Fibric Acid Derivatives,” American Journal of Medicine, Vol. 83, No. Suppl. 5B, 1987, pp. 26-36.

[13]   G. F. Blane, “Review of European Clinical Experience with Fenofibrate,” Cardiology, Vol. 76, No. Suppl. 1, 1989, pp. 1-13.

[14]   B. Davies and T. Morris, “Physiological Parameters in Laboratory Animals and Humans,” Pharmaceutical Research, Vol. 10, No. 7, 1993, pp. 1093-1095.